Laurent, Lucie <br/><br/>
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts.  [electronic resource] 

 -  HPB : the official journal of the International Hepato Pancreato Biliary Association  05 2019 
 - 582-588 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1477-2574 
<br/><br/><label>Standard No.: </label>10.1016/j.hpb.2018.09.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--metabolism<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Bilirubin--metabolism<br/>Biomarkers, Tumor--metabolism<br/>CA-19-9 Antigen--metabolism<br/>Disease Progression<br/>Female<br/>France<br/>Humans<br/>Male<br/>Middle Aged<br/>Pancreatic Neoplasms--metabolism<br/>Retrospective Studies<br/>Sensitivity and Specificity